Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersHematology & Oncology Physician in Omaha, NE
NPI: 1184604118Primary Practice Location
CHI HEALTH LAKESIDE
16901 Lakeside Hills Ct, Omaha, NE
Primary Employer
Oncology Hematology West, PC
nebraskacancer.com
HQ Phone
Get M.D. Margaret's Phone Numberphone_androidMobile
Get M.D. Margaret's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardNE State Medical License
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 782 | 1,957 |
| 2 | 80053Blood test, comprehensive group of blood chemicals | 747 | 1,585 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 613 | 1,196 |
| 4 | 86300Immunologic analysis for detection of tumor antigen | 486 | 839 |
| 5 | 99213Established patient office or other outpatient visit, typically 15 minutes | 321 | 361 |
Preservation of quality of life in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial).
Authors: Erica Stringer-Reasor, Teja Poosarla, Olwen Hahn, Louis Fehrenbacher, Jorge Ramos, Erika Hamilton, Andrew Brenner
Publication Date: 2021-05-10
Reply to T. Shimoi et al and Y. Shimanuki et al.
Authors: Shabana Dewani, Antonio Wolff, Chirag Jani, Erica Mayer, Craig Mescher, Angela Demichele, Kimberly Morley, Ben Park, Bernard Tawfik, Brian Burnette, Eve Rodler, Della Makower, Amye Tevaarwerk, William Sikov, Lisa Flaum, Joseph Sparano
Journal: J Clin Oncol
Publication Date: 2021-09-23
Authors: Lowell Hart, Angela Demichele, Karen Tedesco, Ian Krop, Paul Marcom
Journal: NPJ Breast Cancer
Publication Date: 2021-06-11
Lead Sponsor: Ambrx, Inc.
Intervention / Treatment: DRUG: ARX788
Lead Sponsor: EQRx, Inc.
Intervention / Treatment: DRUG: Lerociclib + Letrozole or Fulvestrant
Lead Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Intervention / Treatment: DRUG: Placebo, DRUG: Trastuzumab, DRUG: Pertuzumab, DRUG: Tucatinib, DRUG: Combination product: Trastuzumab + Pertuzumab
